2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Robertson MN, Platt H. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. Annals Of Internal Medicine 2022, 175: 1221-1229. PMID: 35939812, DOI: 10.7326/m21-4119.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyLong-term extension studyHCV reinfectionDrug useExtension studyAgonist therapySuccessful treatmentHepatitis C virus (HCV) reinfectionHepatitis C virus infectionBenefits of cureC virus infectionChronic HCV infectionRate of reinfectionUrine drug screeningOngoing drug useClinical trial sitesSubsidiary of MerckHCV infectionCohort studyVirus reinfectionDohme Corp.Treatment completionGenotype 1Virus infectionHigh risk
2020
The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL. The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction 2020, 116: 83-93. PMID: 32428276, PMCID: PMC7674222, DOI: 10.1111/add.15115.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOAT discontinuationAgonist therapyTreatment retentionIndependent predictorsHIV epidemicCost-effective HIV prevention strategyMethadone maintenance treatment patientsObservational longitudinal cohort studySpecialty addictions treatmentBuprenorphine maintenance treatmentHigh dosageHIV prevention strategiesLongitudinal cohort studyOpioid-dependent peopleTreatment discontinuationCohort studyMaintenance treatmentMale sexTreatment patientsPrevention strategiesDiscontinuationYounger ageCenter settingAddiction treatment
2019
Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations
Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations. BMC Infectious Diseases 2019, 19: 913. PMID: 31664910, PMCID: PMC6819597, DOI: 10.1186/s12879-019-4443-z.Peer-Reviewed Original ResearchConceptsViral loadART adherenceAdherence measuresSelf-reported antiretroviral therapy (ART) adherenceCriminal justice-involved populationsSelf-reported ART adherenceLogistic regressionSelf-reported health statusContinuum of HIVDetectable viral loadPlasma viral loadAIDS Research NetworkAntiretroviral therapy adherenceAssociation of adherenceHealth status levelsVisual analog scaleViral load dataMixed-effects logistic regressionMixed effects linear regressionEffects linear regressionJustice-involved populationsEffects logistic regressionVL outcomesCD4 countART doses
2017
Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic
Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. International Journal Of Drug Policy 2017, 48: 44-53. PMID: 28800420, PMCID: PMC5603251, DOI: 10.1016/j.drugpo.2017.05.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMedication-assisted treatment programTB test resultsTwelve-month retentionCare delivery systemCorrelates of retentionEvidence-based strategiesTB patientsMultivariable analysisOpioid dependenceAgonist treatmentHIV transmissionClinical recordsHIV epidemicOAT programsPatient retentionHigher dosingHigh dosesTreatment programPatientsSurvival analysis methodsDosingTuberculosisElectronic monitoring systemTreatmentCohort profile: seek, test, treat and retain United States criminal justice cohort
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsTreatment cascadeViral loadHIV RNA viral loadCD4 T-cell countRisk behaviorsSubstance useT-cell countsHepatitis C infectionRNA viral loadInjection drug useHealth Related QualityHIV treatment cascadeUnprotected sexual intercourseHealth care accessRecent polysubstance useC infectionViral suppressionHIV diagnosisHIV infectionMedian ageRelated qualityCriminal justice involvementART treatmentCohort members
2014
Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers
Haddad MS, Zelenev A, Altice FL. Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers. Journal Of Urban Health 2014, 92: 193-213. PMID: 25550126, PMCID: PMC4338126, DOI: 10.1007/s11524-014-9924-1.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyPrimary care providersPrimary health care settingsHealth care screeningQualified health centersHealth care settingsOpioid dependenceHealth centersPsychiatric specialistsUrban Federally Qualified Health CenterFederally Qualified Health CentersOpioid-dependent womenPrimary care screeningObservational cohort studyOpioid-dependent patientsHuman immunodeficiency virusProportion of subjectsHealth care indicatorsHealth care outcomesImproved health outcomesElectronic health recordsUrban FQHCsHepatitis CMaintenance therapyCohort studyEmergency Department Use among HIV-Infected Released Jail Detainees
Boyd AT, Song DL, Meyer JP, Altice FL. Emergency Department Use among HIV-Infected Released Jail Detainees. Journal Of Urban Health 2014, 92: 108-135. PMID: 25331820, PMCID: PMC4338130, DOI: 10.1007/s11524-014-9905-4.Peer-Reviewed Original ResearchConceptsHIV primary careEmergency department useED visitsPrimary careHIV careED useDepartment useDrug severitySubstance useCox proportional hazards regressionUnique ED visitsProportional hazards regressionMultivariate negative binomial regressionHIV/AIDSRecent substance useHealth care continuityPrimary outcomeHazards regressionCare continuityFemale sexMedical recordsJail detentionJail detaineesNegative binomial regressionPotential covariatesOptimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2013
Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes
Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes. Drug And Alcohol Dependence 2013, 131: 127-135. PMID: 23332439, PMCID: PMC3674170, DOI: 10.1016/j.drugalcdep.2012.12.008.Peer-Reviewed Original ResearchConceptsQualified health centersSubstance abuse counselingHealth centersBuprenorphine maintenance treatment programCocaine useBuprenorphine maintenance therapyConcomitant cocaine useOpioid-dependent patientsMaintenance treatment programReal-world effectivenessSubstance abuse treatment outcomesElectronic health recordsHCV infectionMaintenance therapyPsychiatric comorbidityMean ageDependent patientsPsychiatric medicationsClinical trialsTreatment outcomesMood disordersFamily practitionersMore weeksTreatment programBMT
2012
Early Identification of HIV: Empirical Support for Jail-Based Screening
de Voux A, Spaulding AC, Beckwith C, Avery A, Williams C, Messina LC, Ball S, Altice FL. Early Identification of HIV: Empirical Support for Jail-Based Screening. PLOS ONE 2012, 7: e37603. PMID: 22662177, PMCID: PMC3360747, DOI: 10.1371/journal.pone.0037603.Peer-Reviewed Original ResearchConceptsAntiretroviral treatmentClient-level dataCD4 countHIV testingMedian CD4 countRoutine HIV testingInitial CD4 countTime of diagnosisInjection drug useYounger median ageUnprotected anal intercourseCross-sectional analysisAntiretroviral therapyMedian agePharmacy costsDisease progressionAnal intercoursePost dischargeSubset of individualsNew diagnosisDrug useEarly identificationDiagnosisCells/Baseline dataRetention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence
Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. Journal Of Substance Use And Addiction Treatment 2012, 43: 451-457. PMID: 22534003, PMCID: PMC3419304, DOI: 10.1016/j.jsat.2012.03.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentHealthcare utilizationED utilizationEmergency department usageOpioid-dependent patientsEmergency department utilizationLate-stage diseaseTreatment-seeking patientsBuprenorphine treatmentChart reviewPerson yearsED useMaintenance treatmentOpioid dependenceDependent patientsPrimary careHospitalizationDrug usersNegative binomial regressionBinomial regressionPatientsComparison of timeTreatmentAverage lengthStay
2011
Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine
Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D. Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s83-s90. PMID: 21317600, PMCID: PMC3066190, DOI: 10.1097/qai.0b013e31820bc9a5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBuprenorphineBuprenorphine, Naloxone Drug CombinationCohort StudiesFemaleGuideline AdherenceHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPractice Guidelines as TopicQuality of Health CareConceptsBUP/NXHIV careOpioid dependenceHIV qualitySummary quality scoresCare indicatorsBuprenorphine/naloxone maintenance therapyHigh-quality HIV careOpioid-dependent HIVRole of buprenorphineObservational cohort studyOpioid-dependent patientsQuality scoresNondependent patientsHIV clinicMaintenance therapyCohort studyBuprenorphine treatmentClinical outcomesMultivariable analysisMedical recordsPatientsCareMonthsHIVHepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatment
2009
A Prospective Controlled Trial of Routine Opt-Out HIV Testing in a Men's Jail
Kavasery R, Maru DS, Sylla LN, Smith D, Altice FL. A Prospective Controlled Trial of Routine Opt-Out HIV Testing in a Men's Jail. PLOS ONE 2009, 4: e8056. PMID: 19946371, PMCID: PMC2777336, DOI: 10.1371/journal.pone.0008056.Peer-Reviewed Original ResearchConceptsRoutine optHIV testingProspective Controlled TrialTesting groupMen's jailProportion of menPreliminary positive resultsPrimary outcomeControlled TrialsJail detaineesMultivariate analysisDisease controlHIVLower likelihoodWeek periodHigh ratePositive resultsTrialsGroupMale inmatesNew HavenOptimal timeJailEarly releaseTesting
2007
Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2004
Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount
2000
Prevention of HIV Infection in Street-Recruited Injection Drug Users
Monterroso E, Hamburger M, Vlahov D, Jarlais D, Ouellet L, Altice F, Byers R, Kerndt P, Watters J, Bowser B, Fernando D, Holmberg S. Prevention of HIV Infection in Street-Recruited Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 25: 63-70. DOI: 10.1097/00126334-200009010-00009.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug usersHIV infectionInitial serum specimensLarge multicity studyHIV prevention strategiesHIV infection riskHIV prevention programsSyringe exchange programsDrug treatment programsUse of needlesNew AIDSHIV acquisitionHIV serostatusHIV casesPrevention strategiesSerum specimensSex partnersInfection ratePrevention programsTreatment programInfection riskStandard questionnaireHIVMultivariate modelPrevention of HIV Infection in Street-Recruited Injection Drug Users
Monterroso E, Hamburger M, Vlahov D, Jarlais D, Ouellet L, Altice F, Byers R, Kerndt P, Watters J, Bowser B, Fernando M, Holmberg S. Prevention of HIV Infection in Street-Recruited Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 25: 63-70. PMID: 11064506, DOI: 10.1097/00042560-200009010-00009.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug usersHIV infectionInitial serum specimensLarge multicity studyHIV prevention strategiesHIV infection riskHIV prevention programsSyringe exchange programsDrug treatment programsUse of needlesNew AIDSHIV acquisitionHIV serostatusHIV casesPrevention strategiesSerum specimensSex partnersInfection ratePrevention programsTreatment programInfection riskStandard questionnaireHIVMultivariate model